Join the club for FREE to access the whole archive and other member benefits.
Groundbreaking drug is called aducanumab, which targets a protein called amyloid
Key points from article :
Currently, 850,000 people in the UK live with dementia.
There haven't been any new dementia drugs in over a decade.
Higher doses of aducanumab can provide a significant benefit to patients with early Alzheimer's.
Aducanumab could get regulatory approval in the US in early 2020 according to Biogen.
Click on resource name for more details.
Company specialized in the discovery, development, and delivery of therapies for the treatment of neurological diseases
